Intercellular Adhesion Molecule 1 (CD54) Market Size, Definition 2016 Global Markets Direct's, 'Intercellular Adhesion M | Page 2

- The report covers pipeline products based on various stages of development ranging from pre-registration till
discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description,
descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus
Receptor or CD54) targeted therapeutics and enlists all their major and minor projects
- The report assesses Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54)
targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group
Rhinovirus Receptor or CD54) targeted therapeutics
Reasons To Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain
competitive advantage
- Identify and understand the targeted therapy areas and indications for Intercellular Adhesion Molecule 1 (ICAM-1
or Major Group Rhinovirus Receptor or CD54)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Intercellular Adhesion Molecule 1 (ICAM-1 or
Major Group Rhinovirus Receptor or CD54) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope
Buy a Sample Copy of This Report @ http://www.radiantinsights.com/research/intercellular-adhesionmolecule-1/request-sample
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) Overview 6
Therapeutics Development 7
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Products under
Development by Stage of Development 7
Intercell ular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Products under
Development by Therapy Area 8
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Products under
Development by Indication 9
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Pipeline Products
Glance 10
Late Stage Products 10
Early Stage Products 11
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Products under
Development by Companies 12
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Products under
Development by Universities/Institutes 14